Drug-Makers Paying Off Competitors To Keep Cheap Generics Off Market | Talking Points Memo

Republicans and their allies in the business community talk a good game about the virtues of free-market competition. But, as we’ve seen in the debate over the public option, that stance often goes out the window when corporate profits are at stake.


This is a companion discussion topic for the original entry at https://talkingpointsmemo.com/?p=133950